Is Halozyme's EU Injunction on Subcutaneous Keytruda Reshaping Merck's Investment Case?
FROM THE WIRE · FINANCE.YAHOO.COM
In late September 2026, a Dutch court ruled in favor of Halozyme Therapeutics, issuing an injunction that halts manufacture and sale of Merck's subcutaneous Keytruda in eight European countries following a patent dispute. This setback affects one of Merck's key immuno-oncology…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishA Dutch court ruling favoring Halozyme halts Merck's subcutaneous Keytruda sales in 8 European countries, impacting its portfolio.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01A Dutch court issued an injunction favoring Halozyme Therapeutics in late September 2026.
- 02The injunction halts manufacture and sale of Merck's subcutaneous Keytruda in eight European countries.
- 03The ruling reflects a patent dispute affecting product access and Merck's portfolio planning.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Merck & Co., Inc.142.79 USDMarket closedtoday +0.60%Negative Halozyme Therapeutics, Inc.110.79 USDMarket closedtoday +0.98%Positive
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets